4.7 Article

Preparation and Evaluation of a Horse Antiserum against the Venom of Sea Snake Hydrophis curtus from Hainan, China

Journal

TOXINS
Volume 14, Issue 4, Pages -

Publisher

MDPI
DOI: 10.3390/toxins14040253

Keywords

Hydrophis curtus; sea snake venom; antivenom; first aid

Funding

  1. National Key R&D Program of China [2019YFC0312605]
  2. National Natural Science Foundation of China [81974496]

Ask authors/readers for more resources

Sea snake bites can be effectively treated by injecting sea snake antivenom. However, there is currently no effective antivenom for sea snake bites in China. In this study, a high-titer Hydrophis curtus antivenom was prepared by immunizing horses, and it showed cross-neutralizing capacity against different sea snake venoms. In vivo assessment demonstrated improved survival rates and alleviation of organ injuries in envenomated mice after injection of the antivenom.
Sea snake venom is extremely toxic, and it can induce severe respiratory failure and cause high mortality. The most effective first aid treatment for sea snake bites is to inject antivenom as soon as possible. However, in China, there are only four types of terrestrial snake antivenoms, none of which are effective in the treatment of sea snake bites. In order to develop an antivenom for the dominant species of sea snakes in Chinese seas, Hydrophis curtus venom (HcuV) was chosen as the antigen to immunize horses. From immune plasma, a high-titer Hydrophis curtus antivenom (HcuAV) was prepared. In vitro assessment showed that HcuAV had a cross-neutralizing capacity against HcuV and Hydrophis cyanocinctus venom (HcyV). In vivo assessment indicated that HcuAV injection could significantly improve the survival rates of the HcuV and HcyV envenomated mice (0% to 100% and 87.5%, respectively) when it was injected at a sufficient amount within the shortest possible time. In addition, HcuAV could also effectively alleviate multiple organ injuries caused by HcuV. These results provide experimental support for the future clinical application of HcuAV.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available